ClinicalTrials.gg

Program

STSP-0902

A development code. Also written as “STSP-0902 ophthalmic solution” and “STSP-0902 injection”.

Its studies are mostly in Oligospermia · Keratitis · Asthenozoospermia, led by Staidson (Beijing) Biopharmaceuticals.

Furthest: phase 2, since Apr 15, 20255 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Staidson (Beijing) Biopharmaceuticals53 open or runningphase 2since Apr 15, 2025Jul 2, 2024Sep 2027phase 2 · NCT07833943

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 2, 2024First study: phase 1 study in OligospermiaFirst studyNCT06563713 · 40 enrolled · China
  2. Sep 9, 2024Phase 1 study in Neurotrophic KeratitisNCT06597422 · 82 enrolled · China
  3. Apr 15, 2025Phase 2 study in Neurotrophic KeratitisNCT06975748 · 48 planned · China
  4. Apr 21, 2025Phase 1 study in OligospermiaNCT06948799 · 64 planned · China
  5. Sep 13, 2026Phase 2 study in Oligozoospermia and/or AsthenozoospermiaNCT07833943 · 72 planned · China

Ahead

  1. Sep 2027Primary completion: phase 2 study in Oligozoospermia and/or AsthenozoospermiaNCT07833943

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07833943Oligozoospermia and/or Asthenozoospermia · China2Not yet recruitingSep 202772
NCT06948799Oligospermia · China1RecruitingJul 202664
NCT06975748Neurotrophic Keratitis · China2RecruitingApr 202648
NCT06597422Neurotrophic Keratitis · China1CompletedJan 23, 202582
NCT06563713Oligospermia · China1CompletedFeb 24, 202540

How it is read

Names in the registry

  • “STSP-0902 ophthalmic solution”, 6 entries
  • “STSP-0902 injection”, 3 entries

Codes read as this program: STSP0902.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
STSP-0902 (Staidson (Beijing) Biopharmaceuticals): development program | ClinicalTrials.gg